We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Concerned About Biosimilarity Statement Recommended in Biosimilar Labeling Guidance
Industry Concerned About Biosimilarity Statement Recommended in Biosimilar Labeling Guidance
Despite the FDA extending the comment period for its recommendations on biosimilar labeling, several industry groups have still made public their concerns about the draft guidance.